Century Therapeutics (IPSC) files $150M ATM shelf with TD Cowen
Century Therapeutics (IPSC) has filed a prospectus supplement to register an "at-the-market" (ATM) shelf offering of up to $150 million in common stock through TD Cowen. Approximately $131.6 million remains available under this offering, with sales to be made at market prices and TD Cowen receiving a 3.0% commission. The net proceeds are intended for general corporate purposes, including research, clinical development, manufacturing, working capital, and capital expenditures.
MAR 13·Simply Wall St→
Century Therapeutics (IPSC) Swings To US$0.51 EPS Profit Challenging Persistent Loss Narratives
Century Therapeutics (IPSC) reported a significant swing to a basic EPS profit of US$0.51 for the first half of 2025, with revenues of US$109.2 million, contrasting its prior periods of losses. Despite this positive half-year performance, the company still maintains a net loss of US$9.6 million over the trailing twelve months, and analysts forecast a decline in earnings over the next three years. The article discusses how this recent profitability challenges previous narratives of persistent losses but highlights the fragility of earnings and the company's valuation below its biotech peers.
AUG 22·GlobeNewswire→
Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
PHILADELPHIA, Aug. 22, 2025 ( GLOBE NEWSWIRE ) -- Century Therapeutics, Inc. ( 'Century', NASDAQ: IPSC ) , an innovative biotechnology company developing induced pluripotent stem cell ( iPSC ) -derived cell therapies in autoimmune disease and cancer, today announced that Brent Pfeiffenberger, ...
